Federal Circuit Issues a Decision in Classen v. Biogen

On August 31, 2011, the Court of Appeals for the Federal Circuit issued a 2-1 decision holding that two of Classen Immunotherapies Inc.’s patents for evaluating a vaccine immunization schedule contained a patent eligible process while the third related patent did not.

Please click here to view the opinion.